Publications by authors named "Emma K Link"
Article Synopsis
- The study aimed to assess the effectiveness of adding ipilimumab to nivolumab treatment in patients with advanced, non-clear-cell renal cell carcinoma who showed disease progression on nivolumab alone.
- In a phase 2 trial, patients received nivolumab for up to 12 months, then ipilimumab if their condition worsened; the response rates were relatively low, with notable treatment-related adverse events.
- Despite modest overall effects of nivolumab alone, some participants did respond well, and the combination treatments continued to show some promise in managing the disease.
Background: N-methyl-2-pyrrolidone (NMP) is an epigenetically active chemical fragment and organic solvent with numerous applications including use as a drug-delivery vehicle. Previously considered biologically inert, NMP demonstrates immunomodulatory and anti-myeloma properties that are partly explained by acetyllysine mimetic properties and non-specific bromodomain inhibition. We therefore evaluated orally administered NMP in a phase 1 dose-escalation trial to establish its maximum tolerated dose (MTD) in patients with relapsed/refractory multiple myeloma (RR-MM).
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to determine if adding a tumour bed boost after whole breast irradiation (WBI) improves outcomes for women with non-low-risk ductal carcinoma in situ (DCIS) post-surgery, focusing on local recurrence rates.
- - Conducted as a phase 3 trial across 11 countries, 1,608 women participated, receiving either no boost or a boost after either conventional or hypofractionated WBI, with 6.6 years of median follow-up.
- - Results showed the boost group had a significantly lower local recurrence rate (97.1%) compared to the no-boost group (92.7%), although the boost also led to higher reports of breast pain.
Background: BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and whole breast radiotherapy. Here, we report the effects of diagnosis and treatment on health-related quality of life (HRQOL) at 2 years.
View Article and Find Full Text PDF